

Preferred Drug List (PDL) News: January 1, 2024 PDL changes

PREFERRED			
Abacavir Sulfate solution	Abacavir Sulfate tablet	Abilify Asimtufil [®] (aripiprazole)	Azasite [®] ophthalmic solution (azithromycin)
Cabenuva [®] Kit (cabotegravir/ rilpivirine)	Dextroamphetamine 24 SR	Dhivy [®] (carbidopa/levodopa) #	Emflaza [®] (deflazacort) #
Endari [®] (L-glutamine) #	Eylea [®] (afibercept)	Febuxostat	Firvanq [®] solution (vancomycin HCl)
Gelnique [®] (oxybutynin)	Kesimpta [®] (ofatumumab) #	Kloxxado [®] (naloxone)	Lansoprazole ODT Solutabs (age <12)
Lopinavir/ritonavir	Lotemax [®] 0.5% gel (loteprednol etabonate ophthalmic)	Lucentis [®] (ranibizumab)	Lyrica [®] capsules (pregabalin)
Lyrica [®] solution (pregabalin)	Ofloxacin ophthalmic solution	Olopatadine 0.6% Nasal Spray	Omeprazole/Sodium Bicarb capsules
Oxytrol [®] (oxybutynin)	Protonix [®] packets (pantoprazole) (age <12)	Rebiny [®] (Coagulation Factor IX (recombinant), GlycoPEGylated)	Revatio [®] Suspension (sildenafil) #
Tobramycin w/dexamethasone ophthalmic suspension	Tolterodine	Tolterodine ER	Trospium
Vancomycin capsules	Xeljanz [®] oral solution (tofacitinib) #	Xiidra [®] ophthalmic solution (lifitegrast)	Zegerid [®] RX capsules (omeprazole/sodium bicarb)
Zioptan [®] (tafluprost) ophthalmic solution			

To review the complete PDL please refer to:

<https://dvha.vermont.gov/providers/pharmacy/preferred-drug-list-pdl-clinical-criteria>

Note:

*Indicates that current uses will be grandfathered.

Indicates that the drug will require a clinical Prior Authorization

Preferred Drug List (PDL) News: January 1, 2024 PDL changes

NON-PREFERRED			
Alprolix® (coagulation factor IX (recombinant), Fc fusion protein) *	Beovu® (brolucizumab-dbl)	Bismuth Subcitrate, Metronidazole, Tetracycline capsules	Brimonidine Tartrate 0.1% ophthalmic solution
Brinzolamide 1% ophthalmic solution	Byooviz™ (ranibizumab-nuna)	Cimduo™ (lamivudine/tenofovir)*	Cimerli® (ranibizumab-eqrn)
Cosopt® (dorzolamide/timolol)	Darunavir*	Dexlansoprazole capsules	Dorzolamide w/timolol ophthalmic solution
Eylea® HD (afibercept)	Fesoterodine ER	Idelvion® (coagulation factor IX (recombinant), Albumin fusion protein (rIX-FP)) *	Kaletra® (lopinavir/ritonavir)
Konvomep® suspension (omeprazole and sodium bicarbonate)	Lansoprazole, Amoxicillin, Clarithromycin pack	Lisdexamfetamine capsules	Nevanac® (nepafenac) ophthalmic suspension
Norvir® (ritonavir)	Omeprazole/Sodium bicarb packet	Oriahnn® (elagolix, estradiol and norethindrone acetate and elagolix) capsules*	Orilissa® (elagolix)*
Pantoprazole packets	Phospholine iodine	Pirfenidone tablets	Prezista® (darunavir)*
SPS® suspension (sodium polystyrene sulfonate)	Susvimo® (ranibizumab)	Symfi™ (efavirenz/lamivudine/tenofovir disoproxil fumarate)*	Symfi™ Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate)*
Tafluprost ophthalmic solution	Timolol maleate PF dropperette	Timoptic® Ocudose PF	Vabysmo® (faricimab-svoa)
Zegerid® RX packets (omeprazole/sodium bicarb)	Ziagen® solution (abacavir sulfate)		

To review the complete PDL please refer to:

<https://dvha.vermont.gov/providers/pharmacy/preferred-drug-list-pdl-clinical-criteria>

Note:

*Indicates that current uses will be grandfathered.

Indicates that the drug will require a clinical Prior Authorization